Novel immunotherapies in multiple myeloma - chances and challenges

被引：24
|
作者：
Rasche, Leo [1 ,2 ]
Wasch, Ralph [3 ]
Munder, Markus [4 ,5 ]
Goldschmidt, Hartmut [6 ,7 ]
Raab, Marc S. [6 ,8 ]
机构：
[1] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany
[2] Univ Hosp Wurzburg, Mildred Scheel Early Career Ctr, Wurzburg, Germany
[3] Univ Freiburg, Fac Med, Univ Med Ctr, Dept Internal Med 1, Freiburg, Germany
[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany
[5] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy, Mainz, Germany
[6] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany
[7] Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[8] German Canc Res Ctr, CCU Mol Hematol Oncol, Heidelberg, Germany
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
T-CELL THERAPY; CAR-T; EXPRESSION; CD38;
D O I：
10.3324/haematol.2020.266858
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma. We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in the management of multiple myeloma. We also focus on the selection of patients for these therapies and speculate as to how best to individualize treatment approaches. We see these novel immunotherapies as representing a paradigm shift. However, despite the promising preliminary data, many open issues remain to be evaluated in future trials.
引用
收藏
页码：2555 / 2565
页数：11
相关论文
共 50 条
  • [41] Extramedullary Multiple Myeloma: Challenges and Opportunities
    Ho, Matthew
    Paruzzo, Luca
    Minehart, Janna
    Nabar, Neel
    Noll, Julia Han
    Luo, Thomas
    Garfall, Alfred
    Zanwar, Saurabh
    CURRENT ONCOLOGY, 2025, 32 (03)
  • [42] Immunotherapy of Multiple Myeloma: Promise and Challenges
    Abramson, Hanley N.
    IMMUNOTARGETS AND THERAPY, 2021, 10 : 343 - 371
  • [43] Novel approaches and cutting edge immunotherapies in multiple sclerosis
    Bauman, TM
    Kasper, LH
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 : 2302 - 2322
  • [44] Proteomics: addressing the challenges of multiple myeloma
    Ge, Feng
    Tao, Shengce
    Bi, Lijun
    Zhang, Zhiping
    Zhang, Xian'En
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2011, 43 (02) : 89 - 95
  • [45] Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma
    Reina-Ortiz, Chantal
    Giraldos, David
    Azaceta, Gemma
    Palomera, Luis
    Marzo, Isabel
    Naval, Javier
    Villalba, Martin
    Anel, Alberto
    CELLS, 2022, 11 (03)
  • [46] RESCUER - Data harmonization of multiple clinical trials - challenges and chances
    Lehle, Sarah
    Ernst, Mathias
    Braso-Maristany, Fara
    Prat, Aleix
    Engebraten, Olav
    Hatschek, Thomas
    Foukakis, Theodoros
    Kyte, Jon Amund
    Rubner, Matthias
    Uhrig, Sabrina
    Beckmann, Matthias
    Fasching, Peter Andreas
    Kristensen, Vessela N.
    Huebner, Hanna
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 36 - 36
  • [47] Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
    Barila, Gregorio
    Rizzi, Rita
    Zambello, Renato
    Musto, Pellegrino
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 19
  • [48] Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
    Camille Guillerey
    Kyohei Nakamura
    Slavica Vuckovic
    Geoffrey R. Hill
    Mark J. Smyth
    Cellular and Molecular Life Sciences, 2016, 73 : 1569 - 1589
  • [49] Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
    Guillerey, Camille
    Nakamura, Kyohei
    Vuckovic, Slavica
    Hill, Geoffrey R.
    Smyth, Mark J.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2016, 73 (08) : 1569 - 1589
  • [50] Novel therapies, for multiple myeloma
    Ryoo, JJ
    Cole, CE
    Anderson, KC
    BLOOD REVIEWS, 2002, 16 (03) : 167 - 174
12345